CROs/Service Providers

MedSource expands footprint, adds new service line

Monday, September 18, 2017

Houston-based CRO MedSource is growing its service-offering to include the early stages of clinical development and pipeline planning through Investigational New Drug (IND) submissions. The service, rarely offered by CROs, will be provided by a new department—Scientific Development—which will be responsible for delivering a suite of clinical development services to biotech and pharmaceutical companies wishing to organize their pipeline strategy, prioritize indications, and develop strategies that will efficiently advance new drug candidates into the clinic. The enhanced offering establishes MedSource as a partner that can offer its expertise throughout the entire drug development process, in complement to the execution of clinical trials that has been a mainstay for its 20-year history.

[Read More]

Science Exchange signs on as LabCentral sponsor

Wednesday, August 30, 2017

Biotech innovation hub LabCentral has signed Science Exchange, a secure platform for outsourced research and development (R&D), as a sponsor to support its life science and biotech resident startups. Companies within LabCentral’s shared workspaces are now able to order R&D services instantly via a customized Science Exchanged-powered marketplace, with access to more than 2,500 qualified scientific service providers.

[Read More]

Parcom Capital acquires Viroclinics Biosciences

Wednesday, August 30, 2017

Viroclinics, founded in 2001 and specializing in testing new vaccines and drugs in the clinical trial stages prior to their market launch, has been acquired by Parcom Capital. Viroclinics has clients across the globe and conducts virology testing for clients that include the world’s top 10 biopharmaceutical companies. The company is also a market leader in the Netherlands. For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.

[Read More]

PPD, HealthCore expand real-world research capabilities

Monday, August 28, 2017

PPD and HealthCore are building upon their existing collaboration to include Evidera, PPD’s peri- and post-approval business unit. The addition of Evidera will help enable the companies to address post-marketing safety commitments in Europe and the U.S., and expand the relationship to include other studies evaluating outcomes in real-world settings.

[Read More]